Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jaad.2023.08.019 | DOI Listing |
Transplant Cell Ther
January 2025
Department of Psychiatry, Massachusetts General Hospital, Boston, MA; USA; Harvard Medical School, Boston MA; USA.
Background: CAR T-cell therapy (CAR-T) is leading to durable responses in patients with cancer but there is concern that cytokine release syndrome (CRS) and neurotoxicity may impact survivors' cognitive function. We assessed long-term cognitive function in CAR-T recipients and examine factors associated with change in cognition over time.
Methods: We assessed perceived cognition (Functional Assessment of Cancer Therapy - Cognition) and neurocognitive performance (standardized neuropsychological battery) in adult patients prior to receiving CAR-T and at 6 month follow-up.
Gastrointest Endosc
January 2025
Department of Gastroenterology, St Vincent's Hospital, Melbourne, Australia; University of Melbourne, Melbourne, Australia. Electronic address:
Background & Aims: There is conflicting literature describing the durability of complete remission of intestinal metaplasia (CRIM) after endoscopic eradication therapy (EET) for Barrett's esophagus (BE). We aim to assess the timeline, predictors and long-term outcomes of recurrence.
Methods: Data on 365 patients who underwent EET for dysplastic BE were collected prospectively between 2008 and 2022 at a Barrett's referral unit.
Chem Commun (Camb)
January 2025
Materials Chemistry Laboratory, Department of Chemistry, School of Natural Sciences, Shiv Nadar Institution of Eminence, Gautam Buddha Nagar, Uttar Pradesh 201314, India.
Cathode materials with both high capacity and high operating voltage are essential for advancing aqueous zinc-ion batteries (ZIBs). Conventional high-capacity materials, such as vanadium-based compounds, typically deliver low discharge voltages. In contrast, organic cathodes show high operating voltages but often exhibit limited capacity.
View Article and Find Full Text PDFCurr Opin Oncol
December 2024
Université Libre de Bruxelles, Hôpital Universitaire de Bruxelles, Instiut Jules Bordet, Departement of Medical Oncology.
Purpose Of Review: This review evaluates by analyzing recent studies whether pathological complete response (pCR) can be used as a reliable surrogate marker for overall survival (OS) in melanoma treated with neoadjuvant immunotherapy.
Recent Findings: Trials like Neo-Combi, Neo-Trio and COMBI-Neo show that pCR is crucial for long-term success in targeted therapy for melanoma, while studies like OpACIN-neo and SWOG S1801 demonstrate that immunotherapy can provide durable benefits even with partial responses. Findings from NADINA and the INMC analysis highlight that immunotherapy achieves higher pathologic response rates and improved survival outcomes, offering broader benefits compared to the pCR-dependent outcomes of targeted therapy.
Am J Health Syst Pharm
January 2025
Department of Pharmacy Practice, Auburn University Harrison College of Pharmacy, Auburn, AL, USA.
Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!